{
  "report_rows": [
    {
      "kpi": "Q2 2026 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$6.65B vs. cons $6.56B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$3.51 vs. cons $3.46",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 adjusted operating margin",
      "prediction": "IN-LINE",
      "answer": "pred ~25.6% vs. cons 25.4%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 organic sales growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~8.75% midpoint vs. cons 8.7% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 adjusted EPS",
      "prediction": "UNCHANGED",
      "answer": "guide ~$15.00 midpoint vs. cons $14.98 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 adjusted operating-margin expansion",
      "prediction": "BETTER",
      "answer": "guide ~50 bps vs. cons 45 bps (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.6,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.5,
  "day5_path": "FADE",
  "day5_rationale": "The Q2 beat validates recovery, but an unchanged FY2026 EPS midpoint of ~$15.00 less predicted H1 EPS of ~$6.11 implies H2 EPS of ~$8.89 vs. pre-print consensus of ~$8.92, producing modest out-period estimate cuts and a partial fade.",
  "day5_confidence": "MEDIUM"
}